SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

The real controversy behind Trump’s $100,000 Truth Social service

Black Hat 2026: Israeli cyber companies unveil AI defenses for the age of autonomous attacks

Ireland's new government jet may face limits in fog after Israeli landing system was left off

Deel crosses $1.5 billion ARR, strengthening IPO credentials

Buzz

Most popular

Daily

Weekly

1

Billionaire Beny Steinmetz challenges $1.4 million tax demand over $9 million Israeli home sale

2

Salesforce veterans raise $20 million pre-Seed from Marc Benioff and Michael Dell to tackle AI’s enterprise bottleneck

3

Wix's Base44 bet comes at a price as losses widen to $76.4 million

4

Monday seeks to double CEO pay weeks after announcing 620 layoffs

5

Visa acquires Israeli fraud prevention company BioCatch for $2.4 billion

Mori Arkin

5 stories about Mori Arkin

Exalenz Bioscience Acquired for $49M

19.02.20|Golan Hazani

Israeli-born billionaire & biomed entrepreneur Mori Arkin sold his company for 6.10 NIS per share. Learn more on CTech!

Biomed Entrepreneur Mori Arkin Nearing Sale of Exalenz to a U.S. Company

19.02.20|Golan Hazani

Tel Aviv-listed Exalenz is not considered one of the serial entrepreneur’s great successes, having lost 73% of its valuation over the past five years. The current deal will see it sold at a premium of tens of percentages, according to one source

סטפן אושמן מנכ"ל Merck

Merck and WuXi AppTec Announce Launch of Biotech Incubator in Israel

20.02.18|Meir Orbach

The incubator program has a five year budget of 20 million euros

Acne Cream Developer Sol-Gel files for $86 Million Nasdaq IPO

31.08.17|Dror Reich

The clinical-stage drug developer will remain a "controlled company" under current shareholder Arkin Dermatology

Anti-Acne Drug Developer Plans Nasdaq IPO

15.08.17|Golan Hazani

Sol-Gel approached potential underwriters. It aims to go public before the end of the year